Abcam, ab249206, Anti-SLAMF6 antibody [EPR9916] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SLAMF6 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9916,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249206 is the carrier-free version of
ab155951
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SLAMF6 also known as CD352 is a protein that functions as a signaling lymphocytic activation molecule. It is a member of the SLAM family and is found on the surface of many immune cells including T cells B cells and natural killer (NK) cells. SLAMF6 has a molecular weight of approximately 71 kDa. This protein plays a role in cell-to-cell adhesion and transduction of activation signals. Its expression appears prominently in lymphoid tissues directing immune responses.
Biological function summary
SLAMF6 assists in modulating immune cell interactions and is part of specific receptor complexes. It influences the activation and proliferation of immune cells and contributes to the maintenance of immune homeostasis. SLAMF6 interacts with signaling pathways involving SAP (SLAM-associated protein) and EAT-2 which facilitate downstream signaling events essential for immune cell function and communication.
Pathways
SLAMF6 integrates within the SLAM receptor signaling pathway impacting the regulation of immune responses. It plays a role in the NF-kB signaling pathway important for inflammatory and immune responses. Related proteins in these pathways include SAP and EAT-2 important in signal transduction cascades that affect cell survival differentiation and function of immune cells.
SLAMF6 ties to autoimmune diseases and certain cancers. It is involved in autoimmune conditions such as systemic lupus erythematosus where malfunction in immune regulation occurs. Additionally deregulation of SLAMF6 expression associates with lymphomas impacting cell communication and immune function. In these conditions SLAMF6 interacts with SAP influencing the disease progression through altered immune signaling pathways.